On April 21, 2023, the Board of Directors of Compass Therapeutics, Inc. approved the appointment of a new director to its Board: Richard S. Lindahl, MBA, who is currently the executive vice president, chief financial officer, and treasurer of Emergent BioSolutions, Inc. The Board, upon recommendation of its Nominating and Corporate Governance Committee, appointed Mr. Lindahl as a Class III director, effective immediately to fill a vacant Class III Board seat, with a term expiring at the Company's annual meeting of stockholders in 2023. Mr. Lindahl was also appointed to serve as a member and chairman of the Company's Audit Committee. The Board determined that Mr. Lindahl is an independent director and meets the requirements of audit committee financial expert status under the Company's corporate governance guidelines and applicable Nasdaq Listing Rules.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.105 USD | -0.45% | -9.09% | -29.49% |
May. 28 | Compass Therapeutics Appoints Thomas Schuetz as CEO | MT |
May. 28 | Compass Therapeutics, Inc. Announces CEO Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.49% | 153M | |
+17.45% | 124B | |
+18.68% | 112B | |
+3.52% | 22.94B | |
-11.44% | 17.02B | |
-16.50% | 16.88B | |
-39.57% | 16.87B | |
+2.66% | 13.63B | |
+24.37% | 11.61B | |
+106.03% | 10.31B |
- Stock Market
- Equities
- CMPX Stock
- News Compass Therapeutics, Inc.
- Compass Therapeutics, Inc. Appoints Richard S. Lindahl as Class III Director, Member and Chairman of the Audit Committee